An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
This is an extension study of ABT-806 for subjects with advanced solid tumors.
Advanced Solid Tumors
DRUG: ABT-806
Safety (Number of subjects with adverse events), Evaluation of vitals signs, clinical lab testing and adverse event monitoring (every other week), physical exam (every 4 weeks) and ECG (at final visit), At each treatment visit (every other week throughout the study or up to 51 weeks)|Pharmacokinetic profile (assay for ABT-806), Assay for ABT-806, Every 8 weeks starting at Week 9 throughout the study or up to 51 weeks
This is an extension study of ABT-806 for subjects with advanced solid tumors.